Press Releases



    • NOV 11 2020

    ONC201 and ONC206 Efficacy in Brain Tumors to be Presented at 2020 SNO Conference

    Philadelphia, PA (November 11, 2020) – Oncoceutics, Inc. announced that the latest research on imipridones ONC201 and ONC206 for the treatment of brain tumors will be presented at the 2020 Society of Neuro-Oncology Virtual Annual Meeting to be held November 19th-21st. These data will highlight clinical and translational findings over the past year, including: Updated

    • NOV 05 2020

    Oncoceutics Receives Foundation Grants to Establish an Expanded Access Program for ONC201

    Philadelphia, PA (November 5, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, announced today that it has received grants from Michael Mosier Defeat DIPG Foundation, Dragon Master Foundation and The ChadTough Foundation to fund an Expanded Access program for ONC201 in the United States. The program will allow Oncoceutics to work with physicians